Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Molecular Partners (MOLN – Research ...
Mereo BioPharma Group plc (NASDAQ:MREO – Get Free Report) has been given an average rating of “Buy” by the seven brokerages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results